Literature DB >> 123251

Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

P C Harpel, N R Cooper.   

Abstract

This study has explored the nature of the molecular events which occur when C1 inactivator, a human plasma inhibitor of the complement, kinin-forming, coagulation, and fibrinolytic enzyme systems, interacts with C1s, plasmin, and trypsin. Purified inhibitor preparations demonstrated two bands, when examined by acrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS). The molecular weights of the major and minor bands were 105,000 and 96,000 daltons, respectively. The minor component appeared to be immunologically and functionally identical to the main C1 inactivator component. Loss of C1s and plasmin functional activity was associated with the formation of a 1:1 molar complex between the inhibitor and each enzyme. These complexes were stable in the presence of SDS and urea. The light chain of both these enzymes provided the binding site for C1 inactivator. Complex formation and enzyme inhibition occurred only with native and not with an inhibitor preparation denatured by acid treatment, thereby demonstrating the importance of conformational factors in the enzyme-inhibitor reaction. Although peptide bond cleavage of the C1 inactivator molecule by C1s was not documented, plasmin was found to degrade the inhibitor with the production of several characteristic derivatives. At least one of these products retained the ability to complex with C1s and plasmin. Trypsin, which failed to form a complex with C1 inactivator, degraded the inhibitor in a limited and sequential manner with the production of nonfunctional derivatives one of which appeared structurally similar to a plasmin-induced product. These studies therefore, provide new information concerning the molecular interactions between C1 inactivator and several of the proteases which it inhibits.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 123251      PMCID: PMC301788          DOI: 10.1172/JCI107967

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Interaction of a serum inhibitor of C'I-esterase with intermediate complexes of the immune haemolytic system. I. Specificity of inhibition of C'I activity associated with intermediate complexes.

Authors:  I H LEPOW; M A LEON
Journal:  Immunology       Date:  1962-03       Impact factor: 7.397

2.  Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.

Authors:  N S LANDERMAN; M E WEBSTER; E L BECKER; H E RATCLIFFE
Journal:  J Allergy       Date:  1962 Jul-Aug

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

5.  [Isolation and characterization of C1-Inactivator from human plasma].

Authors:  H Haupt; N Heimburger; T Kranz; H G Schwick
Journal:  Eur J Biochem       Date:  1970-12

6.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

7.  Group-specific adsorption of glycoproteins.

Authors:  K Aspberg; J Porath
Journal:  Acta Chem Scand       Date:  1970

8.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

9.  Inhibition of Hageman factor activation.

Authors:  H L Nossel; H Rubin; M Drillings; R Hsieh
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

10.  Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

View more
  48 in total

Review 1.  Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base.

Authors:  R Clive Landis; Jeremiah R Brown; David Fitzgerald; Donald S Likosky; Linda Shore-Lesserson; Robert A Baker; John W Hammon
Journal:  J Extra Corpor Technol       Date:  2014-09

2.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 3.  [Hepatology. New research results in its significance for the understanding of liver diseases].

Authors:  W Gerok; H E Blum; W Offensperger; S Offensperger; T Andus; V Gross; P C Heinrich
Journal:  Naturwissenschaften       Date:  1991-06

4.  Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

Authors:  M H Prandini; A Reboul; M G Colomb
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

5.  Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury.

Authors:  Valeria Ramaglia; Ruud Wolterman; Maryla de Kok; Miriam Ann Vigar; Ineke Wagenaar-Bos; Rosalind Helen Mary King; Brian Paul Morgan; Frank Baas
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 6.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

7.  The primary inhibitor of plasmin in human plasma.

Authors:  S Müllertz; I Clemmensen
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

8.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  The purification and characterization of subcomponent C1s of the first component of bovine complement.

Authors:  R D Campbell; N A Booth; J E Fothergill
Journal:  Biochem J       Date:  1979-12-01       Impact factor: 3.857

10.  Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene.

Authors:  N J Levy; N Ramesh; M Cicardi; R A Harrison; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.